November, 2024
November 2024
M T W T F S S
 123
45678910
11121314151617
18192021222324
252627282930  
Paolo Tarantino: ADCs combine the potency of chemotherapy with the PK of mAbs
Nov 1, 2024, 07:37

Paolo Tarantino: ADCs combine the potency of chemotherapy with the PK of mAbs

Paolo Tarantino, Fellow at Dana-Farber Cancer Institute, shared a post on X:

“ADCs combine the potency of chemo with the PK of mAbs. This translates into increased antitumor activity, but also in delayed toxicities. The most common, with T-DXd: nausea. Check this interesting Annals Oncology editorial on the ERICA randomized trial.”

Beyond the Usual Window: Persistent Nausea with Trastuzumab Deruxtecan Calls for New Management Strategies

Author: K. Jordan

Paolo Tarantino

More posts featuring Paolo Tarantino.

Dr. Paolo Tarantino, MD, is pursuing an advanced research fellowship at Dana-Farber Cancer Institute and Harvard Medical School, concurrently working towards a PhD in clinical research at the University of Milan.

His research focuses on exploring the HER2 oncoprotein, investigating the emerging HER2-low subgroup of breast tumors, and developing novel antibody-drug conjugates targeting every subtype of breast cancer. With a publication record exceeding 50 papers on breast cancer, he is recognized as a leading expert in the field.